Biomedical

Georgia State University is planning to construct an $84 million research building in Atlanta for the study of global infectious diseases. Designed by HOK, the 84,100-sf biocontainment facility will provide BSL-3 and BSL-4 labs, a vivarium, collaborative open research areas, offices, and support space. A design-bid-build contractor is being sought for the project, which has an estimated construction cost of $66 million. The structure represents the third phase of development at the university's Science Park and is slated for completion in 2022.

Vermeulens has released its market outlook report for the fourth quarter of 2019. Key points include:

Fujifilm Diosynth Biotechnologies began construction in March of 2020 on a $14.5 million campus in Billingham in the United Kingdom. Designed by Ryder Architecture, the project will support the creation of innovative biologic, vaccine, and gene therapy products. Accommodating approximately 300 employees, the campus will feature a 42,000-sf office building with an inviting welcome center. Completion is expected in March of 2021. Additional R&D laboratories and manufacturing facilities will be delivered in a subsequent phase of development. 

Oregon Health & Science University is constructing the $50 million Elks Children's Eye Clinic Building in Portland. Designed by NBBJ, the freestanding 64,000-sf building will be physically connected to the existing Casey Eye Institute by a striking glass sky bridge. The five-story structure will accommodate translational research labs, an 11,500-sf pediatric eye clinic, and space for clinical trials.

Amicus Therapeutics opened the $25 million Global Research and Gene Therapy Center of Excellence in March of 2020 in Philadelphia. Accommodating up to 200 employees, the 75,000-sf project provides collaborative labs and offices to support the discovery and development of new therapies for rare metabolic diseases.

Washington University in St. Louis broke ground on a $616 million neuroscience research center in March of 2020. Designed by Perkins+Will and CannonDesign, the 609,000-sf building will accommodate over 100 research teams in collaborative neighborhoods to promote interaction. Strategically sited between the university's medical campus and the Cortex Innovation Community, the 11-story facility will house approximately 900 investigators from the departments of neurology, neuroscience, neurosurgery, psychiatry, and anesthesiology.

East Carolina University is constructing the $90 million Life Sciences and Biotechnology Building in Greenville, N.C. Designed by Lord Aeck Sargent, the 141,500-sf facility will provide wet bench and computational labs for programs in biotechnology, biophysics, biofuels, environmental engineering, imaging, and sensor development. Enabling students to engage in collaborative research with academic and industry partners, the four-story structure will include classrooms, lecture halls, administrative offices, core labs, and support spaces.

Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.

The Texas A&M University System is creating a $546 million complex at the Texas Medical Center in Houston. A renovated 18-story structure will accommodate the groundbreaking Engineering Medicine (EnMed) program when it opens in summer of 2020. Two new towers will be developed through a public-private partnership (P3). Slated for completion in June of 2022, a 365,000-sf residential facility will offer 572 units providing 704 beds for medical and nursing students, and a 1.2 million-sf parking garage will accommodate 3,444 cars.

The University of Pittsburgh and the University of Pittsburgh Medical Center are building the Immune Transplant and Therapy Center in Bloomfield. Developed in partnership with Wexford Science & Technology, the $250 million project involves the transformation of a former Ford assembly plant and showroom into an eight-story innovation hub accommodating research on immunotherapy, cancer, chronic diseases, aging, and transplantation.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are planning to break ground in fall of 2020 on the $750 million Cancer Pavilion in New Brunswick. Created in partnership with the New Brunswick Development Corporation (DEVCO), the 12-story, 510,000-sf structure will enable the consolidation of key cancer services in a single integrated location.

Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.

Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies.

Eli Lilly and Company opened the 11,500-sf Lilly Life Sciences Studio in San Diego in January of 2020. Part of a $90 million investment to expand the company's research footprint, the laboratory leverages a robotic cloud platform created by Strateos to enable other drug discovery companies and investigators to access the remote-controlled facility.

Foghorn Therapeutics broke ground in January of 2020 on its 60,000-sf headquarters in Cambridge, Mass. Located in Kendall Square, the facility will provide chemistry and biology labs, open offices, conference rooms, huddle rooms, and an employee café. Foghorn will occupy over three floors in the building, which is owned by Alexandria Real Estate Equities and managed by CBRE.